Treatment of excessive daytime sleepiness (EDS) or cataplexy in adult patients with narcolepsy; selective histamine H3 receptor inverse agonist/antagonist for enhancing histaminergic neurotransmission and promoting wakefulness; first-in-class non-controlled substance approved for narcolepsy therapy in the US, Europe, and China.